Growth on track but sequentially soft; betting on H2 capacity inflection
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit FY26 30% growth and confirmed 15–20% guidance is appropriate. Q1 YoY +11.7% is in range. But QoQ weakness and margin miss signal lumpiness/transition friction.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Sai is transitioning from small-molecule CRDMO to multi-modality platform (peptides, ADC, formulation, FTE partnerships with 19 of top-25 pharma). Long-term thesis is sound and guidance (15–20% growth, 28–30% EBITDA) is maintained. However, Q1 sequentials are weak: PAT down 29.7% QoQ, OPM 26.7% below target. CDMO growth at 6% YoY lags CRO's 26%, suggesting near-term execution risk. Hold until H2 capacity inflection is evidenced.
₹554.3 Cr
Revenue · +11.7% YoY₹73.3 Cr
Reported PAT · +21.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 12% YoY, momentum across business
METRevenue grew 11.7% YoY (₹554.3 Cr vs ₹496 Cr). QoQ declined -7.9%.
Q1 performance in line with expectations, confident of growth
OVERSTATEDYoY growth okay (11.7%), but PAT down 29.7% QoQ; OPM 26.7% below target 28–30%.
Expect stronger H2 with capacity coming online
METDiscovery capacity in Q1 already sold out; Bidar blocks on track for H2/Q3. Claim credible.
CDMO 60%, CRO 40% split; CRO grew 26% YoY
METCRO ₹~222 Cr at 26% growth. CDMO ₹~332 Cr at 6% growth — weak.
19 of top 25 pharma customers; 90%+ repeat revenue
METCited in call; no contradicting data. Reflects relationship depth.
Earnings quality
What changed since the last call
Capacity utilization acceleration
UpgradeDiscovery capacity Q1 expected to take 1.5 years to fill; now sold out. Early-stage deployment faster than modeled.
FTE partnerships scaling
Upgrade6 late-phase molecules added in 15 months (5 from large pharma FTE). One customer now end-to-end (discovery to commercial). Prior call said 'early stage'; now showing concrete progression.
CDMO growth stalling
DowngradeCDMO +6% YoY in Q1. Prior year FY26 showed stronger momentum. Lumpy but concerning on absolute growth.
Margin guidance unchanged
Neutral28–30% EBITDA target maintained, but Q1 OPM 26.7% below range. No rerate of near-term margin assumptions.
The Q&A
Analysts pressed on specifics: customer metrics (management deflected, won't quantify per-customer revenue), guidance conservatism given pipeline (Siva explained 3–5-year horizon + lumpiness + FY26 was 30%), capacity timeline (Siva said 'on schedule, 1–2 months variance possible'). Management held firm on guidance and deferred on detail, signaling caution.
Big pharma acceleration timing — Binay Singh, Morgan Stanley
PartialKrishna said still 'early stages,' 'gradual increase' expected. Wuxi model took years. India CDMO is first phase (discovery + tech transfer); middle phase (FTE) now migrating. Long way to go in scale.
CRO customer conversion — Amey Chalke, JM Financial
DodgedKrishna said 'integrated platform helped' and 'not one customer, multiple converted.' Won't quantify per-customer revenue.
Commercial product sizing — Amey Chalke, JM Financial
PartialSiva said 'decently sized' (three products), 'lower volume' (one). Primary in two of three. Vague on absolute value per product.
Formulation strategy rationale — Amey Chalke, JM Financial
AnsweredKrishna explained: clinical-only up to Phase 2, not commercial. Driven by customer need for China+1 early clinical supply. Only works with existing development relationships.
Molecule retention post-acquisition — Sajal Kapoor, Antifragile Thinking
PartialKrishna said 'primary intent of every pharma is to leave with us for commercial,' but capacity mismatches possible. Didn't give explicit retention %. Claimed advantages (19 of 25 pharma, preferred vendor status).
Capex hurdle rates — Sajal Kapoor, Antifragile Thinking
AnsweredSiva: internal hurdle rates higher than company ROCE/ROE. Stress-tested vs historical. Capability-building capex hard to defer; capacity-addition capex can modulate. Showed discipline by slowing before when demand slowed.
Capacity timeline execution — Siddharth Negandhi, CWC
AnsweredSiva: 'Largely on schedule, 1–2 months variance.' Discovery capacity Q1 on stream and sold out. Bidar blocks on track for H2/Q3.
AI vs high-throughput experimentation — Siddharth Negandhi, CWC
AnsweredSiva: HTE is multiple scenarios/data points; AI initiative is different—eliminate non-value-add tasks (document generation, literature synthesis). Will update before end of year.
Peptide capability roadmap — Siddharth Negandhi, CWC
AnsweredKrishna: Yes, all three. Not just GLP-1; building broad platform (PDCs, macrocyclic, radiochemistry). Clinical capacity sooner, commercial 2028.
15–20% guidance rationale — Karan Gupta, Asit C. Mehta
PartialSiva: Guidance is over 3–5-year horizon; business is lumpy. Quarter timing drives Q-o-Q volatility. FY26 was exceptional (30%), long-term midpoint is 15–20%. Won't put 'all bets' on higher target—discipline matters.
Biotech acquisition risk — Yasser Lakdawala, M3
AnsweredSiva: 3-way funnel: (1) biotech acquired by pharma Sai works with = stays; (2) pharma's own FTE projects progress to Sai; (3) pharma acquires biotech Sai doesn't know, product transferred due to Sai's preferred vendor status. Pharma relationship is key.
Peptide project portfolio — Dhaval, Jefferies
AnsweredKrishna: Majority work early-stage discovery, multiple customers (large pharma + biotech). One dedicated development lab online. GMP pilot facility coming online (clinical + discovery support). 2028 is true commercial capacity. On chain length: development teams do longer chains (8–12 AA); commercial starts with smaller mature pipelines but seeing demand for longer chains.
ADC pilot scale plans — Dhaval, Jefferies
PartialKrishna: Pilot scale already building. More plans TBD. Significant footprint spans discovery and development for all ADCs.
Guidance
15–20% CAGR over 3–5 years (long-term)
MediumReaffirmed this call. Supported by FTE funnel expansion, late-phase molecule growth (6 in 15 months), and big pharma relationship deepening. But near-term lumpiness acknowledged.
EBITDA 28–30% range (long-term)
MediumMaintained but not evidenced: Q1 OPM 26.7% below range. Capex cycle (₹1,100–1,300 Cr) will depress near-term depreciation. Margins expected to recover post-2028 when capacity is fully utilized.
FY27 capex ₹1,100–1,300 Cr (75% capacity, 25% capability/AI)
HighReaffirmed; on track. Bidar blocks, discovery lab, peptide facility, formulation—aligned with guidance. One-time heavy investment cycle.
Risks the call surfaced
CDMO growth stalling
HighCDMO +6% YoY in Q1 vs CRO +26%. CDMO is 60% of revenue. Weak growth in core business segment suggests capacity/pricing/mix headwinds.
Sequential earnings volatility
HighQ1 PAT down 29.7% QoQ despite 11.7% YoY growth. Business is inherently lumpy but near-term predictability is low. Investors may discount guidance.
Margin compression vs guidance
MediumQ1 OPM 26.7% vs 28–30% target. ₹1,100–1,300 Cr capex cycle will increase depreciation; margins may remain suppressed into FY28. Guidance assumes margin recovery but timing uncertain.
New modality execution risk
MediumPeptide, ADC, formulation capabilities still immature (<5% of revenue). Peptide manufacturing not online until 2028. Formulation 6 months away. Ramp timelines and customer adoption uncertain.
Customer concentration within pharma
MediumWhile 19 of 25 top pharma are customers (diversified), FTE model creates deeper single-customer dependencies. If one large pharma reduces engagement or acquires a competing CDMO, revenue impact is high.
Management
Score 7/10. Transparent on lumpiness and 3–5-year horizon. Deflects on granular customer/segment details ('can't quantify,' 'material non-public information'). Candid on capacity constraints and modular capex discipline. Track record: FY26 30% growth, 17 launches in 5 years, 5 FDA approvals in 2025. Guided 15–20% for 3–5 years; Q1 hit 11.7% YoY. Late-phase pipeline adds 6 in 15 months. Capacity deployments on track (discovery Q1, Bidar H2/Q3). Reaffirm guidance without upgrade.
1 · Q2–Q3 FY27
Bidar manufacturing blocks (225 KL each) come online; discovery facility already sold out
2 · H2 FY27
Second half expected materially stronger than H1 due to capacity ramp-up
3 · FY27 (6 months away)
Formulation capability (oral solids up to Phase 2) operationalized for China+1 early clinical supply
Hold until H2 capacity inflection is evidenced.
Sai Life Sciences Q1 FY27: consolidated PAT up 21% YoY to ₹73 Cr as margins expand
PAT +21.23% YoY · revenue +11.66% · margins expanding
₹554.29 Cr
+11.66% YoY
₹73.29 Cr
+21.23% YoY
13.14%
+1.2pp YoY
₹3.46
Sai Life Sciences' consolidated Q1 FY27 revenue came in at ₹554.29 Cr, up 11.7% YoY from ₹496.42 Cr but down 7.9% QoQ from Q4 FY26's ₹602.14 Cr. Consolidated PAT rose 21.2% YoY to ₹73.29 Cr (basic EPS ₹3.46 vs ₹2.90) but fell 29.7% QoQ from ₹104.24 Cr (EPS ₹4.93). Standalone tracked the same shape — revenue ₹546.73 Cr, PAT ₹71.34 Cr, EPS ₹3.36 — with no material divergence from consolidated. There were no exceptional items in either statement this quarter, so the growth rates above are clean, unadjusted comparisons.
Q1 FY-2027 vs prior quarters
The margin story is YoY expansion against a QoQ pullback. Operating margin (EBITDA/revenue) was 26.70% versus 24.36% a year ago — a 234 bps improvement — but down from Q4 FY26's seasonally strong 29.37%. Net margin followed the same pattern: 13.14% versus 11.94% YoY, down from 16.88% in Q4. The sequential compression tracks the revenue decline itself (CRDMO project revenue is inherently lumpy) rather than any cost blowout — material and other expenses both stepped down QoQ in absolute terms, while employee costs rose modestly on the yearly track.
The stock went into the print at ₹1,414, up 17% over the past month of trading.
What the summary numbers don't show
Deloitte Haskins & Sells issued an unmodified review conclusion on both standalone and consolidated statements
Management reiterated their long-term aspiration of maintaining revenue growth of 15% to 20% and EBITDA margins in the 28% to 30% range over a three-year period. They expect the second half of FY27 to be stronger than the first half due to new capacities coming online. Significant investments are planned, with FY27 cap
— This quarter: met
On guidance, management's prior concall reiterated a three-year aspiration of 15-20% revenue growth and 28-30% EBITDA margins, and explicitly flagged that H2 FY27 should outpace H1 as new capacity comes online. This quarter's 11.7% YoY growth and 26.70% OPM sit below both aspirational bands, but that is consistent with the softer-H1 framing management itself set out rather than a surprise miss. No formal Street consensus specific to Q1 FY27 could be found; full-year FY27 consensus (Simply Wall St, six analysts) pegs revenue near ₹2,650 Cr (~18% growth), which this quarter's print does not yet confirm or contradict on its own. Separately, the company disclosed a ₹32.86 Cr GST demand and penalty in April 2026 — a pre-quarter regulatory matter not reflected as an exceptional item in this result.
W1
H2 FY27 revenue re-acceleration toward management's 15-20% growth aspiration as new capacity comes online, per their own H1-softer/H2-stronger framing
W2
Progress on the ₹1,100-1,300 Cr FY27 capex plan (75% capacity expansion, 25% capability/tech incl. ADCs and peptides) and its effect on asset turn, which management flagged would dip before returning to 1.2x-1.4x
W3
OPM trajectory toward the 28-30% three-year target band from the current 26.70%
Figures converted from Rs. in million to Rs. Crore (÷10); no exceptional items this quarter (prior quarter had an immaterial ₹0.29 Cr labour-code credit, FY26 full year had an ₹8 Cr labour-code exceptional expense — both negligible, no raw/adjusted PAT split needed). Sub-cent rounding differences between line items are conversion artifacts. Both standalone and consolidated statements reviewed (unmodified conclusion) by Deloitte Haskins & Sells LLP.
Q1 FY27: Capex Drag & Margin Pressure — What to Expect From India's CDMO Champion
Sai Life Sciences enters its weakest quarter of FY27, navigating capex ramp-up and Middle East logistics headwinds. The Street expects flat sequential revenue but tighter margins — a near-term pivot from the FY26 surge. The real watch: whether management can hold the 28–30% EBITDA guide through the investment cycle.
What to Expect: The Q1 Setup
Sai Life Sciences enters Q1 FY27 at an inflection: after the torrent of FY26 growth (revenue +29%, EBITDA +56%, PAT +109%), the company now faces capex headwinds and logistics frictions. The Street consensus is clear — this will be the weakest quarter of FY27. Revenue is expected to land near ₹590 Cr (a range of ₹560–620 Cr), with EBITDA margins compressing to 26–29%, well below the FY26 peak of 30%. This is not a business problem; it's a cycle. The question on result day is whether management's guidance — 15–20% revenue CAGR and a sustained 28–30% EBITDA range — remains credible after capex ramp costs are front-loaded into Q1–Q2.
~₹590 Cr
Flat QoQ; Street expects ₹560–620 Cr range
~27.5%
Guidance 26–29%; vs FY26 30% peak
Unknown
Depends on tax rate & finance costs vs capex ramp
₹1,100–1,300 Cr
vs ₹633 Cr in FY26; front-loaded drag
On Track? The FY26–FY27 Handoff
Sai Life Sciences delivered a remarkable FY26: ₹21,532 Cr revenue (vs ₹16,420 Cr prior year), ₹661 Cr EBITDA, and ₹355 Cr PAT. The CDMO segment alone grew 33%, and the CRO/CDMO mix provides diversification most peers lack. Management's long-term guidance (15–20% revenue growth, 28–30% EBITDA margins) remains unchallenged by Wall Street; the debate is only about when margins recover. Q1–Q2 FY27 will see capex investment run at ~₹550–650 Cr per quarter (annualized run-rate ~₹2,200–2,600 Cr before Q3–Q4 moderation). That spend depresses current-quarter margins but fuels future revenue. The trajectory is intact; the tempo is just slower for six months.
What the Street Says
Since Last Quarter: Filing Scan
Operationally quiet. Most filings since Q4 have been routine board notices and insider-trading window closures. Two items merit note:
1 · GST Demand (₹32.86 Cr) — April 2026
Sai Life received a GST notice from Kalaburagi Joint Commissioner (IGST ₹16.28 Cr + interest ₹13.31 Cr + penalty ₹3.25 Cr). Status unknown as of this writing. Management is likely contesting; if settled, the impact would be material but mostly absorbed as a one-time charge. Monitor Q1 call for commentary.
2 · Bidar Campus 100% Renewable Power — May 2026
Positive ESG milestone: Bidar facility (Units IV & VI) now fully renewable-powered. First Indian CRDMO site to achieve this. Largely symbolic, but signals capex discipline — renewable infrastructure is part of the strategic footprint expansion.
The Setup in One Sentence
Sai Life Sciences enters Q1 as the margin-pressure quarter in a multi-year capex cycle — revenue expected flat, EBITDA margins in the 26–29% range (below the 30% FY26 peak and the stated long-term 28–30% target), and the Street watching whether a 27% floor holds or the stock reprices lower. The business is not broken; the quarter is just a pivot. Expect management to re-affirm the 15–20% revenue CAGR and 28–30% EBITDA range and cite Q2–Q3 margin recovery as capex moderates. If margin guidance slips or the GST demand becomes a surprise liability, stocks could test ₹950–₹1,000. If margins hold 28%+, the narrative remains "capex for future growth."
Three things to watch on result day: (1) Actual EBITDA margin — does it clear the 27% floor or dip into the red flag zone? (2) GST demand status — any provision, settlement, or timeline disclosed? (3) FY27 capex guidance — does management reaffirm ₹1,100–₹1,300 Cr, or do Middle East logistics costs push estimates higher? A margin beat and capex discipline could lift the stock; margin miss and capex creep could trigger the ₹950 support test.